Related Experiment Video

Updated: May 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Molecular targets of TRAIL-sensitizing agents in colorectal cancer

Carmine Stolfi1, Francesco Pallone1, Giovanni Monteleone1

  • 1Department of Systems Medicine, University of "Tor Vergata", Via Montpellier 1, Rome 00133, Italy.

International Journal of Molecular Sciences
|September 4, 2012
PubMed

Insights

Natural compounds and synthetic agents can re-sensitize colorectal cancer cells to Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand (TRAIL) therapy. These agents overcome resistance mechanisms, offering new combined treatment strategies for cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) induces cancer cell apoptosis via death receptors (DRs).
  • TRAIL-based therapies are limited by cancer cell resistance, often due to low DR expression or high anti-apoptotic protein levels.
  • Restoring TRAIL sensitivity in resistant cancers is crucial for effective therapeutic strategies.

Purpose of the Study:

  • To investigate the TRAIL-sensitizing effects of natural products and synthetic compounds on colorectal cancer (CRC) cells.
  • To elucidate the molecular mechanisms underlying enhanced TRAIL sensitivity in CRC cells when treated with these compounds.

Main Methods:

  • Utilized colorectal cancer cell lines.
  • Administered natural products and synthetic compounds to induce TRAIL sensitization.
  • Analyzed molecular pathways involved in TRAIL-induced apoptosis and resistance.

Main Results:

  • Identified specific natural products and synthetic compounds that enhance TRAIL-induced apoptosis in CRC cells.
  • Demonstrated that these compounds can overcome common TRAIL resistance mechanisms.
  • Characterized the molecular targets and pathways modulated by these sensitizing agents.

Conclusions:

  • Natural products and synthetic compounds show promise in overcoming TRAIL resistance in colorectal cancer.
  • Combined therapeutic approaches involving TRAIL and sensitizing agents represent a viable strategy for managing CRC.
  • Further research into these compounds could lead to novel cancer treatment protocols.
Keywords:
CHOPDR4DR5caspase-8chemotherapeuticsextrinsic pathwayintrinsic pathwaynatural productsp53survivin

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...